Exicure, Inc. Reports First Quarter 2025 Financial Results

About this update from Exicure, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2431,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/c2aab7ff6cc9269bb304c50c1ee426f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Lor5RfUUuBn9rNj88PHAmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzNztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c2aab7ff6cc9269bb304c50c1ee426f8","width":960,"height":237},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/6gHfWOWPctcdPYYG6XEeTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c2aab7ff6cc9269bb304c50c1ee426f8","width":1200,"height":296}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., June 27, 2025--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the "Company") releases the following financial results for the fiscal quarter ended March 31, 2025.","length":193,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Financial Results","length":36,"tagName":"p"},{"type":"text","content":"Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024.","length":135,"tagName":"p"},{"type":"text","content":"Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("GPCR USA"), which is conducting research. Immediately prior to closing the acquisition of GPCR USA, the Company recorded no research or development expenses.","length":564,"tagName":"p"},{"type":"text","content":"General and Administrative (G&A) Expense: General and administrative expenses were $2.2 million for the quarter ended March 31, 2025, as compared to $1.3 million for the quarter ended March 31, 2024. The increase in G&A expense of $0.9 million for the three months ended March 31, 2025 was mostly due to the additional expenses incurred from the acquisition of GPCR USA and increased professional services compared to the same prior year quarter.","length":454,"tagNa...

More updates from Exicure, Inc.